Array
(
[1596861573] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596862000] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596862081] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596867885] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596870512] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596876571] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596881711] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596881752] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596883600] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596893526] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596894274] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596896953] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596899873] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596902824] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596905811] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596981000] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[66ba68d2add5c4cdada519ad9b8d74a5] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1596981000
)
)
)
)
[1597068000] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1597213490] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
[1597240200] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[df4ffa396e2271a65f97ac47f8578821] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1597240200
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: 14 mayo 2007, 14/05/2007, 14/05/2008, 2005/2006, Abatacept, Agencia Europea de Medicamentos, Antibacterianos, Antidiabéticos, Antidiabéticos orales, Antitrombóticos, Autorizaciones de medicamentos, Citostáticos, Colesevelam, Darunavir, Decitabina, Deferasirox, EMEA, Entecavir, Estiripentol, Eszopiclona, Exenatida, Fanolesomab 99 Tc, FDA, Fluoroquinolonas, Food Drug Administration, Gemtuzumab ozogamicina, Grupo, Hormonas hipotalámicas e hipofisarias, Hormonas liberadores de gonadotropinas, Inmunoestimulantes, Inmunosupresores selectivos, Ivermectina, Laboratorio, Laxantes, Lenalidomida, Lubiprostona, Madrid, Medicamento, medicamentos, Micafungina, Natalizumab, Nepafenaco, Nuevos principios activos, PaM digital, Panitumumab, Panorama Actual del Medicamento, Parches de testosterona, Perflutren, Porfímero, Pramlintida, Principio activo, Rimonabant, Rufinamida, salud, Sanidad, Secretina, Sitaxentán, Telbivudina, Temoporfina, Terapia cardiaca, Ziconotida, Zileuton.
Etiquetas: Actualización de la Información, Actualización sobre restricciones de uso, AEMPS, Agencia española de medicamentos y productos sanitarios, Agonistas dopaminérgicos ergóticos, Azacitidina, BINOCRIT, Cambios de especial interés sanitario en medicamentos ya autorizados, Cetuximab, Comité de Seguridad de Medicamentos de Uso Humano, CSMH, Darunavir, Epoetina alfa, Erbitux, Eszopiclona, Información dirigida a profesionales sanitarios, Información sobre seguridad, informe, Losartán potásico, LUNIVIA, Madrid, medicamentos, Mensual, Nuevas formulaciones de medicamentos ya autorizados, Nuevos medicamentos, octubre 2008, Orlistat, PEGASYS, Peginterferón alfa 2A, PREZISTA, Productos sanitarios, Resumen de la nota informativa, Rimonabant, salud, Sanidad, Terapia Hormonal en la Menopausia, Terapia hormonal sustitutiva, Uso humano, VIDAZA.
.gif)